Top Investment Picks Analysis
Highest-conviction names merged from Sector Rotation, Stage 2/VCP, and the Portfolio Strategy Lab best strategy, with deep technical · fundamental · risk-reward analysis.
- Mechanically-synthesised basket of 10 stocks combining sector-rotation leadership and Weinstein stage-2 momentum, deep-screened across P&L, BS, CF, fundamental scores and corporate events.
- LLM unavailable — rule-based narrative.
- Snapshot 2026-06-19: 975 stocks scanned; Stage 2 count 349 vs Stage 4 173; BUY/STRONG_BUY signals 123; mean RS vs Nifty 500 12.7%.
- Equal-weight 10% per name baseline.
- Overweight HIGH-conviction names by +2%, halve LOW-conviction sizes.
- Cap sector exposure at 30%.
- Scale gross to 60-70% in elevated VIX regimes; cap per-trade risk at 1-2% of NAV via stop-distance × size.
- MTARTECH.
- CUPID.
- PARAS.
- Review sector weights against the spread shown below.
📊 Sector Concentration
📊 Pick Summary — 2026-06-19
| # | Symbol | Sector | Price | Stage | Inv.Score | RS% | 6M Tgt | RR (4M) | Risk | Conviction | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MTARTECH | PSU / CPSE | ₹8374.50 | STAGE_2 | 59.90 | 97.7% | ₹12,222 | 1.39× | 3.5 | HIGH | Strategy+Sector+S2 |
| 2 | PANAMAPET | Other | ₹483.25 | STAGE_2 | 52.80 | 70.7% | ₹684 | 0.83× | 7.5 | MEDIUM | Strategy+S2 |
| 3 | RPTECH | IT & Technology | ₹750.65 | STAGE_2 | 49.70 | 95.2% | ₹1,016 | 0.79× | 6.5 | MEDIUM | Strategy+Sector+S2 |
| 4 | WALCHANNAG | Other | ₹312.05 | STAGE_2 | 48.30 | 82.8% | ₹436 | 1.02× | 5.0 | LOW | Strategy+S2 |
| 5 | CUPID | Other | ₹176.92 | STAGE_2 | 47.50 | 88.1% | ₹247 | 0.88× | 3.5 | HIGH | Strategy+S2 |
| 6 | PARAS | Defence & Aerospace | ₹1408.65 | STAGE_2 | 46.30 | 106.7% | ₹2,123 | 0.82× | 6.5 | HIGH | Strategy+Sector+S2 |
| 7 | LAURUSLABS | Pharma & Healthcare | ₹1412.90 | STAGE_2 | 68.00 | 26.0% | ₹1,690 | 1.18× | 0.5 | MEDIUM | VCP+Sector |
| 8 | SASKEN | IT & Technology | ₹2586.10 | STAGE_2 | 66.00 | 104.0% | ₹3,766 | 1.08× | 5.0 | MEDIUM | VCP+Sector |
| 9 | POLYCAB | Capital Goods & Industrials | ₹10083.00 | STAGE_2 | 65.20 | 28.1% | ₹12,856 | 0.82× | 3.5 | HIGH | VCP+Sector |
| 10 | SATIN | Financial Services | ₹235.43 | STAGE_2 | 62.70 | 46.4% | ₹337 | 1.74× | 3.0 | MEDIUM | VCP+Sector |
📐 Methodology
Top picks are not selected from a single indicator. The report looks for names where market structure, sector strength, price action, strategy evidence, and risk/reward all point in the same direction.
Core Inputs
- Sector Rotation Report — leading sectors and highest investment-score names inside them.
- Stage 2 / VCP Tracker — Weinstein-stage-2 universe plus persisted
scores.stage2_vcp_picks. - Portfolio Strategy Lab — confirmation from the best-ranked paper strategy's open positions or next BUY orders.
- Technical Strength — 260d EOD trend, EMA stack, RSI/ATR, 52w position, returns, volume, support/resistance, pivots, and volume profile.
- Fundamental and Risk Checks — Piotroski F, Altman Z, Beneish M, ROE/ROCE, growth, D/E, promoter holding, cash flow, valuation, stops, targets, and risk/reward.
Weinstein Stage Framework
- Stage 1 — Base / Accumulation: sideways action after a decline; watchlist phase.
- Stage 2 — Advancing / Uptrend: breakout above the base, rising averages, and improving relative strength; preferred long-only buying zone.
- Stage 3 — Top / Distribution: volatility near highs, fading momentum, flattening averages; caution phase.
- Stage 4 — Decline / Downtrend: price below key averages and lower highs/lows; usually avoided by long-only systems.
How Ranking Works
The final rank balances Stage 2 trend quality, relative strength, sector leadership, VCP or breakout evidence, portfolio strategy confirmation, target/stop risk-reward, and fundamental quality. Triple-confirmed names where sector rotation + Stage 2/VCP + strategy evidence agree are prioritised, followed by dual-confirmed candidates with strong trend and acceptable risk.
A high-ranked pick is a research shortlist candidate, not a direct investment instruction. The strongest candidates combine Stage 2 structure, leadership versus the market, constructive sector context, defined stop-loss, and acceptable reward-to-risk.
🔬 Per-Stock Deep Dive
Each card: candlestick chart with EMAs, S/R, pivots & entry/stop/targets · KPI tiles · LLM-narrated thesis · technicals · fundamentals · quarterly / annual / BS / CF · events · risk gauge.
MTARTECH · PSU / CPSE
B What the company does
MTAR develops and manufactures components and equipment for the defense, aerospace, nuclear and clean energy sectors. The company was incorporated in 1970 by the promoters, Mr PR Reddy, Mr KSN Reddy and Mr PJ Reddy, to cater to the technical and engineering needs of the Indian government in the post embargo regime. MTAR has manufacturing footprints in Hyderabad with seven units spread across a 4 km radius and a dedicated export facility as well. [1] In addition, the company also supplies specialised products such.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹8,450 · ₹6,787 · ₹3,920
Pivots — PP ₹8,033 · R1 ₹9,056 · R2 ₹9,737 · S1 ₹7,352 · S2 ₹6,329
💡 Thesis
RS 98% vs Nifty 500 · Momentum RSI 63 · Within 5% of 52w high · PAT YoY +214% · Revenue YoY +67% · OCF/PAT 2.10
📈 Technical View
RSI 62.8, 1Y return —%, dist from 52w high -3.9%.
🏦 Fundamental View
Latest qtr revenue 67.2% YoY, PAT 214.3% YoY; 4Y CAGR revenue 28.4% / PAT 11.4%; ROCE —%; debt trend rising; OCF/PAT 2.10.
🧭 Sector View
Sector strength 57.60
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- OPM expanded 160bps vs 4Q avg
⚠️ Key Risks
- Debt rising ₹+186 Cr (3Y)
🎯 Action
Enter ₹7493-₹8374; stop ₹6393; signal HOLD.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹30.6 × 14x (below-average quality / cyclical) = ₹428 median
- RS 98% vs Nifty 500
- Momentum RSI 63
- Within 5% of 52w high
- Debt rising ₹+186 Cr (3Y)
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹8374.50 (2026-06-19) |
| EMA 20/50/200i | ₹7492.67 / ₹6593.05 / ₹— |
| EMA50 slope (20d)i | 23.10% |
| RSI(14)i | 62.82 |
| ATR(14)i | ₹549.68 (6.56%) |
| 52W High / Lowi | ₹8714.00 / ₹1866.20 |
| From 52W highi | -3.9% |
| Returns 1M/3M/6M/1Yi | 12.3% / 143.6% / 261.6% / — |
| Vol vs 20d avgi | 1.15x |
F Fundamental Scores
| Piotroski F-scorei | 4 / 6 (approx) |
| Altman Z-scorei | 1.72 (Z′ approx) |
| Beneish M-scorei | -2.71 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 11.4% (computed) / 12.9% (computed) |
| Revenue growth (3Y)i | 28.4% (4Y CAGR) |
| PAT growth (3Y)i | 11.4% (4Y CAGR) |
| Debt / Equityi | 0.46 (computed) |
| Promoter holdingi | 30.4% |
| FII / DII holdingi | 17.3% / 27.7% |
| NPMi | 10.7% (computed) |
| EPSi | 30.57 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹8,374.5 |
| EPS (TTM proxy)i | 30.57 |
| P/E (Screener ratios) | 266.0x |
| P/E (derived price ÷ EPS) | 273.9x |
| Market cap (Screener) | ₹25,760 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹267.0 |
| Dividend yield | 0.0% |
| Sales (latest)i | ₹876 Cr (29.6% YoY) |
| PAT (latest)i | ₹94 Cr (77.4% YoY) |
| Net debt (3Y)i | ₹162 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: PSU / CPSE
- Sector strength: 57.60
- Peer avg RS: 32.8% · Avg tech: 57.60 · Avg fund: 52.30
- Sector universe: 24 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹7,493 – ₹8,374 |
| Stop loss | ₹6,393 |
| Target 2M | ₹10,024 |
| Target 4M | ₹11,123 |
| Target 6M | ₹12,222 |
| Reward / Risk (4M) | 1.39× |
| Reward / Risk (6M) | 1.94× |
| Risk per share | ₹1,981 |
| Suggested position size | 8% of portfolio |
Risk score breakdown: ATR 6.6% (+2.5) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 306 | 20 | 44 | 14.40 |
| Dec 2025 | 278 | 23 | 35 | 11.28 |
| Sep 2025 | 136 | 13 | 4 | 1.38 |
| Jun 2025 | 157 | 18 | 11 | 3.51 |
Rev QoQ +10.1% · YoY +67.2% · PAT QoQ +25.7% · YoY +214.3% · OPM vs 4Q avg +160 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 876 | 20 | 94 | 30.57 |
| Mar 2025 | 676 | 18 | 53 | 17.19 |
| Mar 2024 | 581 | 19 | 56 | 18.24 |
| Mar 2023 | 574 | 27 | 103 | 33.62 |
| Mar 2022 | 322 | 29 | 61 | 19.79 |
4Y CAGR — Revenue 28.4% · PAT 11.4% · EPS 11.5%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 377 | 162 | 1743 |
| Mar 2025 | 177 | 177 | 1130 |
| Mar 2024 | 191 | 191 | 1008 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 197 | -353 | -156 |
| Mar 2025 | 101 | -103 | -2 |
| Mar 2024 | 57 | -56 | 1 |
OCF/PAT (latest FY) 2.10 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
- 2026-06-17 — INSIDER BULK_DEAL_SELL Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹133.76 Cr)
- 2026-06-17 — INSIDER BULK_DEAL_BUY Bulk Deal: HRTI PRIVATE LIMITED (₹188.39 Cr)
- 2026-06-17 — INSIDER BULK_DEAL_BUY Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹126.25 Cr)
- 2026-06-17 — INSIDER BULK_DEAL_BUY Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹133.69 Cr)
- 2026-06-17 — BULK_DEAL (BUY): JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED · 156,425 @ ₹8084.34 (≈ ₹126.5 Cr)
- 2026-06-17 — BULK_DEAL (BUY): HRTI PRIVATE LIMITED · 231,111 @ ₹8151.56 (≈ ₹188.4 Cr)
- 2026-06-17 — BULK_DEAL (BUY): JUNOMONETA FINSOL PRIVATE LIMITED · 155,470 @ ₹8120.75 (≈ ₹126.3 Cr)
- 2026-06-17 — BULK_DEAL (BUY): MICROCURVES TRADING PRIVATE LIMITED · 163,800 @ ₹8161.53 (≈ ₹133.7 Cr)
- 2026-06-17 — BULK_DEAL (SELL): HRTI PRIVATE LIMITED · 231,288 @ ₹8151.61 (≈ ₹188.5 Cr)
- 2026-06-17 — BULK_DEAL (SELL): JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED · 156,425 @ ₹8108.51 (≈ ₹126.8 Cr)
📄 Latest Filings Snapshot
- P&L: Sales: 876 Cr (YoY +29.6%); NetProfit: 94 Cr (YoY +77.4%); EPS: 30.57
- Quarterly: Sales last 3Q: 136, 278, 306 Cr; Net Profit last 3Q: 4, 35, 44 Cr
- Ratios: P/E: 266; ROCE: 15.1; ROE: 12.5; Div Yield: 0.00; Book Value: 267; Mkt Cap: 25,760
- Investors: Promoters 30.44% | FII 17.31% | DII 27.66% | Public 24.59%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=59.9, top sector strength=58 · 6 positive · 1 negative factors flagged
PANAMAPET · Other
B What the company does
Panama Petrochem Ltd. was incorporated in 1982 by Amirali E Rayani and is engaged in the conversion and manufacturing of crude oil derivatives to 80+ specialty products across segments. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹409 · ₹367 · ₹323
Pivots — PP ₹448 · R1 ₹525 · R2 ₹566 · S1 ₹407 · S2 ₹330
💡 Thesis
RS 71% vs Nifty 500 · Within 5% of 52w high · PAT YoY +61% · Revenue YoY +18%
📈 Technical View
RSI 80.8, 1Y return —%, dist from 52w high -1.4%.
🏦 Fundamental View
Latest qtr revenue 18.4% YoY, PAT 61.4% YoY; 4Y CAGR revenue 9.5% / PAT -2.0%; ROCE —%; debt trend rising; OCF/PAT -0.33.
🧭 Sector View
Sector strength 78.52
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- OPM expanded 240bps vs 4Q avg
⚠️ Key Risks
- RSI 81 overbought
- Debt rising ₹+85 Cr (3Y)
- OCF/PAT -0.33 weak earnings quality
🎯 Action
Enter ₹367-₹483; stop ₹310; signal BUY.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹35.1 × 14x (below-average quality / cyclical) = ₹492 median
- RS 71% vs Nifty 500
- Within 5% of 52w high
- PAT YoY +61%
- RSI 81 overbought
- Debt rising ₹+85 Cr (3Y)
- OCF/PAT -0.33 weak earnings quality
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹483.25 (2026-06-19) |
| EMA 20/50/200i | ₹366.99 / ₹330.21 / ₹— |
| EMA50 slope (20d)i | 15.80% |
| RSI(14)i | 80.76 |
| ATR(14)i | ₹28.64 (5.93%) |
| 52W High / Lowi | ₹489.90 / ₹229.00 |
| From 52W highi | -1.4% |
| Returns 1M/3M/6M/1Yi | 49.8% / 88.6% / 73.7% / — |
| Vol vs 20d avgi | 6.42x |
F Fundamental Scores
| Piotroski F-scorei | 1 / 6 (approx) |
| Altman Z-scorei | 4.56 (Z′ approx) |
| Beneish M-scorei | -1.83 (watch, simplified) |
| Forensic riski | high (derived) |
| ROE / ROCEi | 14.4% (computed) / 17.4% (computed) |
| Revenue growth (3Y)i | 9.5% (4Y CAGR) |
| PAT growth (3Y)i | -2.0% (4Y CAGR) |
| Debt / Equityi | 0.08 (computed) |
| Promoter holdingi | 63.2% |
| FII / DII holdingi | 11.3% / 0.7% |
| NPMi | 6.9% (computed) |
| EPSi | 35.13 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹483.2 |
| EPS (TTM proxy)i | 35.13 |
| P/E (Screener ratios) | 13.8x |
| Market cap (Screener) | ₹2,923 Cr |
| Market-cap bucketi | SMALL_CAP |
| Book value | ₹243.0 |
| Dividend yield | 1.0% |
| Sales (latest)i | — |
| PAT (latest)i | ₹212 Cr (13.4% YoY) |
| Net debt (3Y)i | ₹62 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Other
- Sector strength: 78.52
- Peer avg RS: 14.5% · Avg tech: 78.52 · Avg fund: 58.65
- Sector universe: 668 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹367 – ₹483 |
| Stop loss | ₹310 |
| Target 2M | ₹569 |
| Target 4M | ₹626 |
| Target 6M | ₹684 |
| Reward / Risk (4M) | 0.83× |
| Reward / Risk (6M) | 1.16× |
| Risk per share | ₹174 |
| Suggested position size | 4% of portfolio |
Risk score breakdown: ATR 5.9% (+2.5) · Near high -1.4% (+1.0) · RSI 81 (+1.5) · Debt rising (+1.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 823 | 11 | 71 | 11.75 |
| Dec 2025 | 775 | 8 | 46 | 7.57 |
| Sep 2025 | 773 | 9 | 53 | 8.76 |
| Jun 2025 | 693 | 8 | 43 | 7.05 |
Rev QoQ +6.2% · YoY +18.4% · PAT QoQ +54.3% · YoY +61.4% · OPM vs 4Q avg +240 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 3064 | 9 | 212 | 35.13 |
| Mar 2025 | 2793 | 9 | 187 | 30.92 |
| Mar 2024 | 2357 | 11 | 195 | 32.26 |
| Mar 2023 | 2249 | 14 | 233 | 38.51 |
| Mar 2022 | 2132 | 14 | 230 | 38.08 |
4Y CAGR — Revenue 9.5% · PAT -2.0% · EPS -2.0%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 111 | 62 | 1919 |
| Mar 2025 | 33 | 14 | 1524 |
| Mar 2024 | 26 | 24 | 1409 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | -69 | -72 | -141 |
| Mar 2025 | 162 | -12 | 150 |
| Mar 2024 | -28 | 66 | 38 |
OCF/PAT (latest FY) -0.33 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: QE SECURITIES LLP (₹19.26 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹23.14 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹16.76 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_SELL Bulk Deal: QE SECURITIES LLP (₹19.30 Cr)
- 2026-06-19 — BULK_DEAL (SELL): JUNOMONETA FINSOL PRIVATE LIMITED · 357,743 @ ₹467.98 (≈ ₹16.7 Cr)
- 2026-06-19 — BULK_DEAL (BUY): QE SECURITIES LLP · 414,194 @ ₹464.92 (≈ ₹19.3 Cr)
- 2026-06-19 — BULK_DEAL (BUY): MICROCURVES TRADING PRIVATE LIMITED · 494,669 @ ₹467.82 (≈ ₹23.1 Cr)
- 2026-06-19 — BULK_DEAL (BUY): JUNOMONETA FINSOL PRIVATE LIMITED · 358,553 @ ₹467.55 (≈ ₹16.8 Cr)
- 2026-06-19 — BULK_DEAL (SELL): QE SECURITIES LLP · 414,210 @ ₹466.02 (≈ ₹19.3 Cr)
- 2026-06-19 — BULK_DEAL (SELL): MICROCURVES TRADING PRIVATE LIMITED · 494,674 @ ₹468.30 (≈ ₹23.2 Cr)
📄 Latest Filings Snapshot
- P&L: Sales: 3,064 Cr (YoY +9.7%); NetProfit: 212 Cr (YoY +13.4%); EPS: 35.13
- Quarterly: Sales last 3Q: 773, 775, 823 Cr; Net Profit last 3Q: 53, 46, 71 Cr
- Ratios: P/E: 13.8; ROCE: 19.2; ROE: 15.6; Div Yield: 1.03; Book Value: 243; Mkt Cap: 2,923
- Investors: Promoters 63.16% | FII 11.28% | DII 0.67% | Public 24.88%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as next buy; current Stage 2 inv=52.8 · 4 positive · 3 negative factors flagged
RPTECH · IT & Technology
B What the company does
Incorporated in 1989, Rashi Peripherals Ltd operates in ICT product distribution business and after-sale services [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹575 · ₹560 · ₹488
Pivots — PP ₹691 · R1 ₹823 · R2 ₹895 · S1 ₹619 · S2 ₹487
💡 Thesis
RS 95% vs Nifty 500 · Within 5% of 52w high · PAT YoY +64% · Revenue YoY +51%
📈 Technical View
RSI 85.4, 1Y return —%, dist from 52w high -1.6%.
🏦 Fundamental View
Latest qtr revenue 51.0% YoY, PAT 64.2% YoY; 4Y CAGR revenue 14.2% / PAT 11.4%; ROCE —%; debt trend rising; OCF/PAT 0.40.
🧭 Sector View
Sector strength 67.62
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- OPM expanded 60bps vs 4Q avg
⚠️ Key Risks
- RSI 85 overbought
- Debt rising ₹+291 Cr (3Y)
🎯 Action
Enter ₹595-₹751; stop ₹512; signal HOLD.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹42.1 × 14x (below-average quality / cyclical) = ₹590 median
- RS 95% vs Nifty 500
- Within 5% of 52w high
- PAT YoY +64%
- RSI 85 overbought
- Debt rising ₹+291 Cr (3Y)
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹750.65 (2026-06-19) |
| EMA 20/50/200i | ₹594.59 / ₹527.96 / ₹— |
| EMA50 slope (20d)i | 16.47% |
| RSI(14)i | 85.45 |
| ATR(14)i | ₹37.88 (5.05%) |
| 52W High / Lowi | ₹762.90 / ₹316.30 |
| From 52W highi | -1.6% |
| Returns 1M/3M/6M/1Yi | 38.1% / 115.1% / 123.9% / — |
| Vol vs 20d avgi | 1.62x |
F Fundamental Scores
| Piotroski F-scorei | 4 / 6 (approx) |
| Altman Z-scorei | 3.96 (Z′ approx) |
| Beneish M-scorei | -2.42 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 13.9% (computed) / 15.8% (computed) |
| Revenue growth (3Y)i | 14.2% (4Y CAGR) |
| PAT growth (3Y)i | 11.4% (4Y CAGR) |
| Debt / Equityi | 0.49 (computed) |
| Promoter holdingi | 64.0% |
| FII / DII holdingi | 0.8% / 17.4% |
| NPMi | 1.8% (computed) |
| EPSi | 42.12 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹750.6 |
| EPS (TTM proxy)i | 42.12 |
| P/E (Screener ratios) | 17.8x |
| Market cap (Screener) | ₹4,947 Cr |
| Market-cap bucketi | MID_CAP |
| Book value | ₹307.0 |
| Dividend yield | 0.3% |
| Sales (latest)i | — |
| PAT (latest)i | ₹282 Cr (34.3% YoY) |
| Net debt (3Y)i | ₹991 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: IT & Technology
- Sector strength: 67.62
- Peer avg RS: 46.6% · Avg tech: 67.62 · Avg fund: 62.08
- Sector universe: 23 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹595 – ₹751 |
| Stop loss | ₹512 |
| Target 2M | ₹864 |
| Target 4M | ₹940 |
| Target 6M | ₹1,016 |
| Reward / Risk (4M) | 0.79× |
| Reward / Risk (6M) | 1.11× |
| Risk per share | ₹239 |
| Suggested position size | 4% of portfolio |
Risk score breakdown: ATR 5.0% (+2.5) · Near high -1.6% (+1.0) · RSI 85 (+1.5) · Debt rising (+1.0) · OCF/PAT watch (+0.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 4489 | 3 | 87 | 12.78 |
| Dec 2025 | 4030 | 3 | 75 | 11.16 |
| Sep 2025 | 4155 | 2 | 59 | 8.88 |
| Jun 2025 | 3152 | 3 | 62 | 9.31 |
Rev QoQ +11.4% · YoY +51.0% · PAT QoQ +16.0% · YoY +64.2% · OPM vs 4Q avg +60 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 15827 | 3 | 282 | 42.12 |
| Mar 2025 | 13773 | 2 | 210 | 31.57 |
| Mar 2024 | 11095 | 3 | 144 | 21.43 |
| Mar 2023 | 9454 | 3 | 123 | — |
| Mar 2022 | 9313 | 3 | 183 | — |
4Y CAGR — Revenue 14.2% · PAT 11.4% · EPS —
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 991 | 991 | 5327 |
| Mar 2025 | 910 | 910 | 4262 |
| Mar 2024 | 700 | 700 | 3819 |
Debt trend rising
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 114 | 19 | 133 |
| Mar 2025 | -299 | 53 | -246 |
| Mar 2024 | -102 | 1 | -101 |
OCF/PAT (latest FY) 0.40 → earnings quality: WATCH
N Corporate Events & Insider Activity (90d)
- 2026-06-17 — INSIDER BULK_DEAL_SELL Bulk Deal: NK SECURITIES RESEARCH PRIVATE LIMITED (₹54.83 Cr)
- 2026-06-17 — INSIDER BULK_DEAL_BUY Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹26.68 Cr)
- 2026-06-17 — INSIDER BULK_DEAL_BUY Bulk Deal: NK SECURITIES RESEARCH PRIVATE LIMITED (₹54.80 Cr)
- 2026-06-17 — INSIDER BULK_DEAL_BUY Bulk Deal: QE SECURITIES LLP (₹50.41 Cr)
- 2026-06-17 — BULK_DEAL (BUY): MICROCURVES TRADING PRIVATE LIMITED · 380,376 @ ₹701.40 (≈ ₹26.7 Cr)
- 2026-06-17 — BULK_DEAL (BUY): NK SECURITIES RESEARCH PRIVATE LIMITED · 777,430 @ ₹704.93 (≈ ₹54.8 Cr)
- 2026-06-17 — BULK_DEAL (BUY): QE SECURITIES LLP · 719,927 @ ₹700.22 (≈ ₹50.4 Cr)
- 2026-06-17 — BULK_DEAL (BUY): JUNOMONETA FINSOL PRIVATE LIMITED · 750,216 @ ₹699.98 (≈ ₹52.5 Cr)
- 2026-06-17 — BULK_DEAL (SELL): MICROCURVES TRADING PRIVATE LIMITED · 380,467 @ ₹701.38 (≈ ₹26.7 Cr)
- 2026-06-17 — BULK_DEAL (SELL): JUNOMONETA FINSOL PRIVATE LIMITED · 757,555 @ ₹700.31 (≈ ₹53.1 Cr)
📄 Latest Filings Snapshot
- P&L: Sales: 15,827 Cr (YoY +14.9%); NetProfit: 282 Cr (YoY +34.3%); EPS: 42.12
- Quarterly: Sales last 3Q: 4,155, 4,030, 4,489 Cr; Net Profit last 3Q: 59, 75, 87 Cr
- Ratios: P/E: 17.8; ROCE: 16.8; ROE: 14.7; Div Yield: 0.27; Book Value: 307; Mkt Cap: 4,947
- Investors: Promoters 64.01% | FII 0.78% | DII 17.45% | Public 17.76%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=49.7, top sector strength=68 · 4 positive · 2 negative factors flagged
WALCHANNAG · Other
B What the company does
Incorporated in 1908, Walchandnagar Industries Ltd is in the Heavy engineering and Foundry & Machine Shop business [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹277 · ₹265 · ₹212
Pivots — PP ₹296 · R1 ₹332 · R2 ₹352 · S1 ₹276 · S2 ₹241
💡 Thesis
RS 83% vs Nifty 500 · Within 5% of 52w high
📈 Technical View
RSI 75.3, 1Y return —%, dist from 52w high -1.2%.
🏦 Fundamental View
Latest qtr revenue —% YoY, PAT —% YoY; —Y CAGR revenue —% / PAT —%; ROCE 4.3%; debt trend —; OCF/PAT —.
🧭 Sector View
Sector strength 78.52
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- Watch next quarterly print
⚠️ Key Risks
- RSI 75 overbought
🎯 Action
Enter ₹261-₹312; stop ₹225; signal HOLD.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 Mid-target from RR-engine 6m level (no EPS in dossier)
- RS 83% vs Nifty 500
- Within 5% of 52w high
- RSI 75 overbought
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹312.05 (2026-06-19) |
| EMA 20/50/200i | ₹260.59 / ₹235.98 / ₹— |
| EMA50 slope (20d)i | 13.95% |
| RSI(14)i | 75.30 |
| ATR(14)i | ₹17.71 (5.68%) |
| 52W High / Lowi | ₹315.80 / ₹131.15 |
| From 52W highi | -1.2% |
| Returns 1M/3M/6M/1Yi | 31.0% / 107.2% / 103.3% / — |
| Vol vs 20d avgi | 1.52x |
F Fundamental Scores
| Piotroski F-scorei | — |
| Altman Z-scorei | — |
| Beneish M-scorei | — |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | -3.8% / 4.3% |
| Revenue growth (3Y)i | — |
| PAT growth (3Y)i | — |
| Debt / Equityi | — |
| Promoter holdingi | 31.6% |
| FII / DII holdingi | 0.5% / 0.8% |
| NPMi | — |
| EPSi | — |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹312.1 |
| EPS (TTM proxy)i | — |
| P/E (Screener ratios) | — |
| Market cap (Screener) | ₹2,117 Cr |
| Market-cap bucketi | SMALL_CAP |
| Book value | ₹52.9 |
| Dividend yield | 0.0% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | — |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Other
- Sector strength: 78.52
- Peer avg RS: 14.5% · Avg tech: 78.52 · Avg fund: 58.65
- Sector universe: 668 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹261 – ₹312 |
| Stop loss | ₹225 |
| Target 2M | ₹365 |
| Target 4M | ₹401 |
| Target 6M | ₹436 |
| Reward / Risk (4M) | 1.02× |
| Reward / Risk (6M) | 1.43× |
| Risk per share | ₹87 |
| Suggested position size | 6% of portfolio |
Risk score breakdown: ATR 5.7% (+2.5) · Near high -1.2% (+1.0) · RSI 75 (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
No quarterly data.
A 5-Year Annual Trajectory
No annual data.
B Balance Sheet (3Y)
No BS data.
C Cash Flow (3Y) & Quality
No CF data.
N Corporate Events & Insider Activity (90d)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: HRTI PRIVATE LIMITED (₹11.51 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_SELL Bulk Deal: HRTI PRIVATE LIMITED (₹10.46 Cr)
- 2026-06-19 — BULK_DEAL (BUY): HRTI PRIVATE LIMITED · 371,235 @ ₹310.16 (≈ ₹11.5 Cr)
- 2026-06-19 — BULK_DEAL (SELL): HRTI PRIVATE LIMITED · 339,316 @ ₹308.23 (≈ ₹10.5 Cr)
- 2026-05-26 — BULK_DEAL (BUY): NK SECURITIES RESEARCH PRIVATE LIMITED · 363,653 @ ₹268.26 (≈ ₹9.8 Cr)
- 2026-05-26 — BULK_DEAL (BUY): HRTI PRIVATE LIMITED · 368,633 @ ₹266.15 (≈ ₹9.8 Cr)
- 2026-05-26 — BULK_DEAL (BUY): QE SECURITIES LLP · 490,981 @ ₹266.30 (≈ ₹13.1 Cr)
- 2026-05-26 — BULK_DEAL (SELL): HRTI PRIVATE LIMITED · 377,685 @ ₹266.15 (≈ ₹10.1 Cr)
📄 Latest Filings Snapshot
- Ratios: P/E: N/A; ROE: -4.01%; Div Yield: 0.00%; Book Value: ₹52.48; Mkt Cap: ₹2119 Cr
- Investors: Promoters 31.59% | FII 0.47% | DII 0.78% | Govt 0.02% | Public 67.14%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=48.3 · 2 positive · 1 negative factors flagged
CUPID · Other
B What the company does
Established in 1993, CUPID Limited is India's premier manufacturer of male and female condoms, personal lubricant, and IVD kits. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹527 · ₹483 · ₹445
Pivots — PP ₹169 · R1 ₹185 · R2 ₹193 · S1 ₹161 · S2 ₹144
💡 Thesis
RS 88% vs Nifty 500 · PAT YoY +200% · Revenue YoY +114% · PAT 3Y CAGR 55% · Net cash ₹19 Cr
📈 Technical View
RSI 85.3, 1Y return —%, dist from 52w high -66.4%.
🏦 Fundamental View
Latest qtr revenue 114.3% YoY, PAT 200.0% YoY; 3Y CAGR revenue 33.9% / PAT 55.0%; ROCE —%; debt trend stable; OCF/PAT 0.43.
🧭 Sector View
Sector strength 78.52
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- OPM expanded 140bps vs 4Q avg
⚠️ Key Risks
- RSI 85 overbought
🎯 Action
Enter ₹149-₹177; stop ₹134; signal BUY.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹0.8 × 35x (premium-quality compounder) = ₹28 median
- RS 88% vs Nifty 500
- PAT YoY +200%
- Revenue YoY +114%
- RSI 85 overbought
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹176.92 (2026-06-19) |
| EMA 20/50/200i | ₹149.12 / ₹149.76 / ₹— |
| EMA50 slope (20d)i | -1.40% |
| RSI(14)i | 85.28 |
| ATR(14)i | ₹7.59 (4.29%) |
| 52W High / Lowi | ₹526.95 / ₹74.60 |
| From 52W highi | -66.4% |
| Returns 1M/3M/6M/1Yi | 48.1% / 124.7% / -55.1% / — |
| Vol vs 20d avgi | 1.63x |
F Fundamental Scores
| Piotroski F-scorei | 4 / 6 (approx) |
| Altman Z-scorei | 4.29 (Z′ approx) |
| Beneish M-scorei | -1.71 (high, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 24.0% (computed) / 28.7% (computed) |
| Revenue growth (3Y)i | 33.9% (3Y CAGR) |
| PAT growth (3Y)i | 55.0% (3Y CAGR) |
| Debt / Equityi | 0.12 (computed) |
| Promoter holdingi | 46.0% |
| FII / DII holdingi | 1.0% / 0.2% |
| NPMi | 30.2% (computed) |
| EPSi | 0.80 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹176.9 |
| EPS (TTM proxy)i | 0.80 |
| P/E (Screener ratios) | 220.0x |
| P/E (derived price ÷ EPS) | 221.1x |
| Market cap (Screener) | ₹23,790 Cr |
| Market-cap bucketi | MICRO_CAP |
| Book value | ₹3.4 |
| Dividend yield | 0.0% |
| Sales (latest)i | ₹358 Cr (95.6% YoY) |
| PAT (latest)i | ₹108 Cr (163.4% YoY) |
| Net debt (3Y)i | ₹-19 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Other
- Sector strength: 78.52
- Peer avg RS: 14.5% · Avg tech: 78.52 · Avg fund: 58.65
- Sector universe: 668 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹149 – ₹177 |
| Stop loss | ₹134 |
| Target 2M | ₹200 |
| Target 4M | ₹215 |
| Target 6M | ₹247 |
| Reward / Risk (4M) | 0.88× |
| Reward / Risk (6M) | 1.63× |
| Risk per share | ₹43 |
| Suggested position size | 4% of portfolio |
Risk score breakdown: ATR 4.3% (+1.5) · RSI 85 (+1.5) · OCF/PAT watch (+0.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 120 | 31 | 36 | 0.27 |
| Dec 2025 | 94 | 37 | 33 | 0.24 |
| Sep 2025 | 84 | 34 | 24 | 0.18 |
| Jun 2025 | 60 | 28 | 15 | 0.11 |
Rev QoQ +27.7% · YoY +114.3% · PAT QoQ +9.1% · YoY +200.0% · OPM vs 4Q avg +140 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 358 | 33 | 108 | 0.80 |
| Mar 2025 | 183 | 23 | 41 | 0.30 |
| Mar 2024 | 172 | 30 | 40 | 0.30 |
| Mar 2021 | 149 | 28 | 29 | 0.22 |
3Y CAGR — Revenue 33.9% · PAT 55.0% · EPS 53.8%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 56 | -19 | 553 |
| Mar 2025 | 19 | -84 | 372 |
| Mar 2024 | 12 | -135 | 320 |
Debt trend stable · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 46 | 28 | 74 |
| Mar 2025 | -11 | 45 | 34 |
| Mar 2024 | 8 | -80 | -72 |
OCF/PAT (latest FY) 0.43 → earnings quality: WATCH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 358 Cr (YoY +95.6%); NetProfit: 108 Cr (YoY +163.4%); EPS: 0.80
- Quarterly: Sales last 3Q: 84, 94, 120 Cr; Net Profit last 3Q: 24, 33, 36 Cr
- Ratios: P/E: 220; ROCE: 33.5; ROE: 27.3; Div Yield: 0.00; Book Value: 3.35; Mkt Cap: 23,790
- Investors: Promoters 46.03% | FII 1.01% | DII 0.17% | Public 52.79%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=47.5 · 5 positive · 1 negative factors flagged
PARAS · Defence & Aerospace
B What the company does
Paras Defence and Space Technologies (PDST) is an Private sector company primarily engaged in the designing, developing, manufacturing, and testing of a variety of defence and space engineering products and solutions. The company caters to four major segments - Defence & Space Optics, Defence Electronics, Heavy Engineering and Electromagnetic Pulse Protection Solutions. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹885 · ₹850 · ₹770
Pivots — PP ₹1,297 · R1 ₹1,554 · R2 ₹1,700 · S1 ₹1,151 · S2 ₹894
💡 Thesis
RS 107% vs Nifty 500 · Within 5% of 52w high · PAT YoY +86% · Revenue YoY +58% · PAT 4Y CAGR 35% · Net cash ₹6 Cr
📈 Technical View
RSI 84.9, 1Y return —%, dist from 52w high -2.4%.
🏦 Fundamental View
Latest qtr revenue 58.3% YoY, PAT 85.7% YoY; 4Y CAGR revenue 27.1% / PAT 34.7%; ROCE —%; debt trend stable; OCF/PAT 0.28.
🧭 Sector View
Sector strength 70.40
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- Watch next quarterly print
⚠️ Key Risks
- RSI 85 overbought
- OCF/PAT 0.28 weak earnings quality
🎯 Action
Enter ₹1047-₹1409; stop ₹872; signal BUY.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹10.9 × 35x (premium-quality compounder) = ₹383 median
- RS 107% vs Nifty 500
- Within 5% of 52w high
- PAT YoY +86%
- RSI 85 overbought
- OCF/PAT 0.28 weak earnings quality
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹1408.65 (2026-06-19) |
| EMA 20/50/200i | ₹1047.17 / ₹904.06 / ₹— |
| EMA50 slope (20d)i | 21.00% |
| RSI(14)i | 84.89 |
| ATR(14)i | ₹87.44 (6.21%) |
| 52W High / Lowi | ₹1443.00 / ₹580.50 |
| From 52W highi | -2.4% |
| Returns 1M/3M/6M/1Yi | 84.9% / 122.0% / 111.1% / — |
| Vol vs 20d avgi | 3.09x |
F Fundamental Scores
| Piotroski F-scorei | 5 / 6 (approx) |
| Altman Z-scorei | 3.28 (Z′ approx) |
| Beneish M-scorei | -1.87 (watch, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 12.3% (computed) / 16.4% (computed) |
| Revenue growth (3Y)i | 27.1% (4Y CAGR) |
| PAT growth (3Y)i | 34.7% (4Y CAGR) |
| Debt / Equityi | 0.04 (computed) |
| Promoter holdingi | 53.2% |
| FII / DII holdingi | 5.1% / 1.2% |
| NPMi | 18.7% (computed) |
| EPSi | 10.93 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,408.7 |
| EPS (TTM proxy)i | 10.93 |
| P/E (Screener ratios) | 132.0x |
| P/E (derived price ÷ EPS) | 128.9x |
| Market cap (Screener) | ₹11,352 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹90.0 |
| Dividend yield | 0.0% |
| Sales (latest)i | ₹477 Cr (30.7% YoY) |
| PAT (latest)i | ₹89 Cr (45.9% YoY) |
| Net debt (3Y)i | ₹-6 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Defence & Aerospace
- Sector strength: 70.40
- Peer avg RS: 56.4% · Avg tech: 70.40 · Avg fund: 57.11
- Sector universe: 9 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹1,047 – ₹1,409 |
| Stop loss | ₹872 |
| Target 2M | ₹1,671 |
| Target 4M | ₹1,846 |
| Target 6M | ₹2,123 |
| Reward / Risk (4M) | 0.82× |
| Reward / Risk (6M) | 1.33× |
| Risk per share | ₹536 |
| Suggested position size | 4% of portfolio |
Risk score breakdown: ATR 6.2% (+2.5) · Near high -2.4% (+1.0) · RSI 85 (+1.5) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 171 | 25 | 39 | 4.27 |
| Dec 2025 | 106 | 25 | 17 | 2.26 |
| Sep 2025 | 106 | 28 | 19 | 2.56 |
| Jun 2025 | 93 | 23 | 14 | 1.84 |
Rev QoQ +61.3% · YoY +58.3% · PAT QoQ +129.4% · YoY +85.7% · OPM vs 4Q avg -60 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 477 | 25 | 89 | 10.93 |
| Mar 2025 | 365 | 27 | 61 | 7.87 |
| Mar 2024 | 254 | 21 | 30 | 4.11 |
| Mar 2023 | 222 | 26 | 36 | 4.62 |
| Mar 2022 | 183 | 29 | 27 | 3.47 |
4Y CAGR — Revenue 27.1% · PAT 34.7% · EPS 33.2%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 27 | -6 | 965 |
| Mar 2025 | 24 | -4 | 852 |
| Mar 2024 | 66 | 44 | 640 |
Debt trend stable · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 25 | -17 | 8 |
| Mar 2025 | 45 | -87 | -42 |
| Mar 2024 | -46 | -2 | -48 |
OCF/PAT (latest FY) 0.28 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
- 2026-06-19 — INSIDER BULK_DEAL_SELL Bulk Deal: NK SECURITIES RESEARCH PRIVATE LIMITED (₹66.33 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: HRTI PRIVATE LIMITED (₹123.32 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: MICROCURVES TRADING PRIVATE LIMITED (₹101.78 Cr)
- 2026-06-19 — INSIDER BULK_DEAL_BUY Bulk Deal: JUNOMONETA FINSOL PRIVATE LIMITED (₹137.81 Cr)
- 2026-06-19 — BULK_DEAL (BUY): QE SECURITIES LLP · 410,168 @ ₹1382.27 (≈ ₹56.7 Cr)
- 2026-06-19 — BULK_DEAL (BUY): NK SECURITIES RESEARCH PRIVATE LIMITED · 476,322 @ ₹1391.97 (≈ ₹66.3 Cr)
- 2026-06-19 — BULK_DEAL (BUY): JUMP TRADING FINANCIAL INDIA PRIVATE LIMITED · 755,182 @ ₹1392.77 (≈ ₹105.2 Cr)
- 2026-06-19 — BULK_DEAL (BUY): HRTI PRIVATE LIMITED · 884,637 @ ₹1394.06 (≈ ₹123.3 Cr)
- 2026-06-19 — BULK_DEAL (BUY): MICROCURVES TRADING PRIVATE LIMITED · 728,697 @ ₹1396.69 (≈ ₹101.8 Cr)
- 2026-06-19 — BULK_DEAL (BUY): JUNOMONETA FINSOL PRIVATE LIMITED · 989,611 @ ₹1392.52 (≈ ₹137.8 Cr)
📄 Latest Filings Snapshot
- P&L: Sales: 477 Cr (YoY +30.7%); NetProfit: 89 Cr (YoY +45.9%); EPS: 10.93
- Quarterly: Sales last 3Q: 106, 106, 171 Cr; Net Profit last 3Q: 19, 17, 39 Cr
- Ratios: P/E: 132; ROCE: 16.9; ROE: 12.6; Div Yield: 0.02; Book Value: 90.0; Mkt Cap: 11,352
- Investors: Promoters 53.20% | FII 5.06% | DII 1.24% | Public 40.52%
Why selected: Portfolio lab best strategy `darvas_box_breakout_v1` confirms as open position; current Stage 2 inv=46.3, top sector strength=70 · 6 positive · 2 negative factors flagged
LAURUSLABS · Pharma & Healthcare
B What the company does
Founded in 2005, Laurus Labs is a research-driven pharmaceutical and biotechnology company having a global leadership position in select Active Pharmaceutical Ingredients (APIs) including anti-retroviral, oncology drugs (including High Potent APIs), Cardiovascular, and Gastro therapeutics. They also offer integrated CMO and CDMO services to Global Innovators from Clinical phase drug development to commercial manufacturing. Laurus employs 6,500+ people, including around 1,050+ scientists, at more than 11 facilities.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹1,457 · ₹1,143 · ₹1,104
Pivots — PP ₹1,393 · R1 ₹1,444 · R2 ₹1,475 · S1 ₹1,362 · S2 ₹1,312
💡 Thesis
Momentum RSI 64 · Within 5% of 52w high · PAT YoY +21% · OCF/PAT 1.82
📈 Technical View
RSI 63.8, 1Y return —%, dist from 52w high -3.0%.
🏦 Fundamental View
Latest qtr revenue 5.3% YoY, PAT 21.0% YoY; 4Y CAGR revenue 8.4% / PAT 1.7%; ROCE —%; debt trend falling; OCF/PAT 1.82.
🧭 Sector View
Sector strength 70.40
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- OPM expanded 420bps vs 4Q avg
⚠️ Key Risks
- No quantitative red flag in dossier
🎯 Action
Enter ₹1371-₹1413; stop ₹1246; signal BUY.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹16.5 × 14x (below-average quality / cyclical) = ₹230 median
- Momentum RSI 64
- Within 5% of 52w high
- PAT YoY +21%
- No quantitative red flag in dossier — confirm qualitative risks
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight mean-reversion; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹1412.90 (2026-06-19) |
| EMA 20/50/200i | ₹1371.17 / ₹1284.49 / ₹— |
| EMA50 slope (20d)i | 11.20% |
| RSI(14)i | 63.84 |
| ATR(14)i | ₹39.54 (2.80%) |
| 52W High / Lowi | ₹1457.00 / ₹864.70 |
| From 52W highi | -3.0% |
| Returns 1M/3M/6M/1Yi | 3.8% / 47.1% / 38.6% / — |
| Vol vs 20d avgi | 1.30x |
F Fundamental Scores
| Piotroski F-scorei | 6 / 6 (approx) |
| Altman Z-scorei | 2.08 (Z′ approx) |
| Beneish M-scorei | -2.74 (low, simplified) |
| Forensic riski | low (derived) |
| ROE / ROCEi | 16.8% (computed) / 17.3% (computed) |
| Revenue growth (3Y)i | 8.4% (4Y CAGR) |
| PAT growth (3Y)i | 1.7% (4Y CAGR) |
| Debt / Equityi | 0.48 (computed) |
| Promoter holdingi | 27.5% |
| FII / DII holdingi | 25.8% / 14.0% |
| NPMi | 13.1% (computed) |
| EPSi | 16.46 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹1,412.9 |
| EPS (TTM proxy)i | 16.46 |
| P/E (Screener ratios) | 85.4x |
| Market cap (Screener) | ₹76,332 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹98.2 |
| Dividend yield | 0.1% |
| Sales (latest)i | — |
| PAT (latest)i | ₹890 Cr (148.6% YoY) |
| Net debt (3Y)i | ₹2,209 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Pharma & Healthcare
- Sector strength: 70.40
- Peer avg RS: 29.8% · Avg tech: 70.40 · Avg fund: 64.94
- Sector universe: 27 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹1,371 – ₹1,413 |
| Stop loss | ₹1,246 |
| Target 2M | ₹1,532 |
| Target 4M | ₹1,611 |
| Target 6M | ₹1,690 |
| Reward / Risk (4M) | 1.18× |
| Reward / Risk (6M) | 1.66× |
| Risk per share | ₹167 |
| Suggested position size | 8% of portfolio |
Risk score breakdown: ATR 2.8% (+0.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 1812 | 28 | 282 | 5.17 |
| Dec 2025 | 1778 | 27 | 252 | 4.66 |
| Sep 2025 | 1653 | 24 | 194 | 3.61 |
| Jun 2025 | 1570 | 24 | 162 | 3.02 |
Rev QoQ +1.9% · YoY +5.3% · PAT QoQ +11.9% · YoY +21.0% · OPM vs 4Q avg +420 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 6813 | 26 | 890 | 16.46 |
| Mar 2025 | 5554 | 19 | 358 | 6.64 |
| Mar 2024 | 5041 | 15 | 162 | 2.98 |
| Mar 2023 | 6041 | 26 | 793 | 14.67 |
| Mar 2022 | 4936 | 29 | 832 | 15.40 |
4Y CAGR — Revenue 8.4% · PAT 1.7% · EPS 1.7%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 2518 | 2209 | 10511 |
| Mar 2025 | 2764 | 2531 | 9336 |
| Mar 2024 | 2577 | 2453 | 8387 |
Debt trend falling
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 1624 | -1086 | 538 |
| Mar 2025 | 602 | -680 | -78 |
| Mar 2024 | 666 | -822 | -156 |
OCF/PAT (latest FY) 1.82 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 6,813 Cr (YoY +22.7%); NetProfit: 890 Cr (YoY +148.6%); EPS: 16.46
- Quarterly: Sales last 3Q: 1,653, 1,778, 1,812 Cr; Net Profit last 3Q: 194, 252, 282 Cr
- Ratios: P/E: 85.4; ROCE: 17.8; ROE: 18.3; Div Yield: 0.14; Book Value: 98.2; Mkt Cap: 76,332
- Investors: Promoters 27.49% | FII 25.82% | DII 13.96% | Public 32.73%
Why selected: VCP-confirmed Stage 2 (vcp=77, inv=68.0) in top-ranked sector Pharma & Healthcare (strength=70) · 4 positive · 0 negative factors flagged
SASKEN · IT & Technology
B What the company does
Established in 1989, Sasken is a specialist in Product Engineering and Digital Transformation providing concept-to-market, chip-to-cognition R&D services to global leaders in Semiconductor, Automotive, Industrials, Consumer Electronics, Enterprise Devices, SatCom, and Transportation industries, etc. Located in India, the company has presence all over the world
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹2,440 · ₹2,359 · ₹1,959
Pivots — PP ₹2,490 · R1 ₹2,877 · R2 ₹3,168 · S1 ₹2,199 · S2 ₹1,812
💡 Thesis
RS 104% vs Nifty 500 · PAT YoY +142% · Revenue YoY +126% · Net cash ₹249 Cr
📈 Technical View
RSI 70.9, 1Y return —%, dist from 52w high -7.0%.
🏦 Fundamental View
Latest qtr revenue 125.7% YoY, PAT 141.7% YoY; 4Y CAGR revenue 26.5% / PAT -17.6%; ROCE —%; debt trend stable; OCF/PAT -0.39.
🧭 Sector View
Sector strength 67.62
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- OPM expanded 400bps vs 4Q avg
⚠️ Key Risks
- RSI 71 overbought
- OCF/PAT -0.39 weak earnings quality
🎯 Action
Enter ₹2185-₹2586; stop ₹1808; signal HOLD.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹35.5 × 14x (below-average quality / cyclical) = ₹497 median
- RS 104% vs Nifty 500
- PAT YoY +142%
- Revenue YoY +126%
- RSI 71 overbought
- OCF/PAT -0.39 weak earnings quality
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight momentum + sector rotation; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹2586.10 (2026-06-19) |
| EMA 20/50/200i | ₹2185.20 / ₹1864.27 / ₹— |
| EMA50 slope (20d)i | 32.61% |
| RSI(14)i | 70.87 |
| ATR(14)i | ₹168.58 (6.52%) |
| 52W High / Lowi | ₹2780.20 / ₹991.00 |
| From 52W highi | -7.0% |
| Returns 1M/3M/6M/1Yi | 50.5% / 157.7% / 115.5% / — |
| Vol vs 20d avgi | 1.67x |
F Fundamental Scores
| Piotroski F-scorei | 3 / 6 (approx) |
| Altman Z-scorei | 3.44 (Z′ approx) |
| Beneish M-scorei | -1.74 (high, simplified) |
| Forensic riski | high (derived) |
| ROE / ROCEi | 6.9% (computed) / 9.1% (computed) |
| Revenue growth (3Y)i | 26.5% (4Y CAGR) |
| PAT growth (3Y)i | -17.6% (4Y CAGR) |
| Debt / Equityi | 0.03 (computed) |
| Promoter holdingi | 43.0% |
| FII / DII holdingi | 18.5% / 1.1% |
| NPMi | 5.3% (computed) |
| EPSi | 35.51 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹2,586.1 |
| EPS (TTM proxy)i | 35.51 |
| P/E (Screener ratios) | 66.6x |
| P/E (derived price ÷ EPS) | 72.8x |
| Market cap (Screener) | ₹3,927 Cr |
| Market-cap bucketi | MID_CAP |
| Book value | ₹563.0 |
| Dividend yield | 1.0% |
| Sales (latest)i | — |
| PAT (latest)i | ₹59 Cr (15.7% YoY) |
| Net debt (3Y)i | ₹-249 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: IT & Technology
- Sector strength: 67.62
- Peer avg RS: 46.6% · Avg tech: 67.62 · Avg fund: 62.08
- Sector universe: 23 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹2,185 – ₹2,586 |
| Stop loss | ₹1,808 |
| Target 2M | ₹3,092 |
| Target 4M | ₹3,429 |
| Target 6M | ₹3,766 |
| Reward / Risk (4M) | 1.08× |
| Reward / Risk (6M) | 1.52× |
| Risk per share | ₹778 |
| Suggested position size | 6% of portfolio |
Risk score breakdown: ATR 6.5% (+2.5) · RSI 71 (+1.0) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 334 | 10 | 29 | 17.77 |
| Dec 2025 | 250 | 10 | 9 | 5.12 |
| Sep 2025 | 255 | 6 | 10 | 6.44 |
| Jun 2025 | 274 | 5 | 10 | 6.24 |
Rev QoQ +33.6% · YoY +125.7% · PAT QoQ +222.2% · YoY +141.7% · OPM vs 4Q avg +400 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 1113 | 8 | 59 | 35.51 |
| Mar 2025 | 551 | 4 | 51 | 33.25 |
| Mar 2024 | 406 | 8 | 79 | 52.21 |
| Mar 2023 | 447 | 23 | 99 | 66.09 |
| Mar 2022 | 434 | 30 | 128 | 85.21 |
4Y CAGR — Revenue 26.5% · PAT -17.6% · EPS -19.7%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 28 | -249 | 1166 |
| Mar 2025 | 26 | -565 | 958 |
| Mar 2024 | 8 | -624 | 926 |
Debt trend stable · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | -23 | 92 | 69 |
| Mar 2025 | -57 | 84 | 27 |
| Mar 2024 | 59 | 6 | 65 |
OCF/PAT (latest FY) -0.39 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
No corporate events, insider transactions, bulk/block deals, or upcoming-calendar items found in the last 90 days across signals.corporate_events, signals.insider_alerts, signals.bulk_block_deals, signals.v_upcoming_events.
📄 Latest Filings Snapshot
- P&L: Sales: 1,113 Cr (YoY +102.0%); NetProfit: 59 Cr (YoY +15.7%); EPS: 35.51
- Quarterly: Sales last 3Q: 255, 250, 334 Cr; Net Profit last 3Q: 10, 9, 29 Cr
- Ratios: P/E: 66.6; ROCE: 10.2; ROE: 7.18; Div Yield: 0.97; Book Value: 563; Mkt Cap: 3,927
- Investors: Promoters 42.95% | FII 18.54% | DII 1.05% | Govt 0.05% | Public 37.40%
Why selected: VCP-confirmed Stage 2 (vcp=80, inv=66.0) in top-ranked sector IT & Technology (strength=68) · 4 positive · 2 negative factors flagged
POLYCAB · Capital Goods & Industrials
B What the company does
Polycab is India’s leading manufacturers of cables and wires and allied products such as uPVC conduits and lugs and glands. We have a range of cables and wires for practically every application. More recently Polycab has also launched a wide range of consumer electrical products like Fans, Switches, Switchgear, LED lights and Luminaries, Solar Inverters, and Pumps.
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹9,833 · ₹8,722 · ₹8,305
Pivots — PP ₹9,893 · R1 ₹10,310 · R2 ₹10,538 · S1 ₹9,665 · S2 ₹9,248
💡 Thesis
Within 5% of 52w high · Revenue YoY +27% · PAT 4Y CAGR 31% · Net cash ₹3169 Cr · OCF/PAT 1.41
📈 Technical View
RSI 72.8, 1Y return —%, dist from 52w high -0.4%.
🏦 Fundamental View
Latest qtr revenue 26.9% YoY, PAT 7.1% YoY; 4Y CAGR revenue 24.0% / PAT 31.1%; ROCE —%; debt trend rising; OCF/PAT 1.41.
🧭 Sector View
Sector strength 67.88
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- Watch next quarterly print
⚠️ Key Risks
- RSI 73 overbought
- Debt rising ₹+75 Cr (3Y)
🎯 Action
Enter ₹9554-₹10083; stop ₹8743; signal BUY.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹177.5 × 35x (premium-quality compounder) = ₹6,212 median
- Within 5% of 52w high
- Revenue YoY +27%
- PAT 4Y CAGR 31%
- RSI 73 overbought
- Debt rising ₹+75 Cr (3Y)
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight mean-reversion; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹10083.00 (2026-06-19) |
| EMA 20/50/200i | ₹9554.50 / ₹9012.93 / ₹— |
| EMA50 slope (20d)i | 9.22% |
| RSI(14)i | 72.80 |
| ATR(14)i | ₹219.21 (2.17%) |
| 52W High / Lowi | ₹10120.00 / ₹6663.00 |
| From 52W highi | -0.4% |
| Returns 1M/3M/6M/1Yi | 9.6% / 41.5% / 39.7% / — |
| Vol vs 20d avgi | 1.63x |
F Fundamental Scores
| Piotroski F-scorei | 4 / 6 (approx) |
| Altman Z-scorei | 3.49 (Z′ approx) |
| Beneish M-scorei | -2.69 (low, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 22.5% (computed) / 31.5% (computed) |
| Revenue growth (3Y)i | 24.0% (4Y CAGR) |
| PAT growth (3Y)i | 31.1% (4Y CAGR) |
| Debt / Equityi | 0.02 (computed) |
| Promoter holdingi | 61.5% |
| FII / DII holdingi | 18.2% / 8.0% |
| NPMi | 9.4% (computed) |
| EPSi | 177.48 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹10,083.0 |
| EPS (TTM proxy)i | 177.48 |
| P/E (Screener ratios) | 60.4x |
| P/E (derived price ÷ EPS) | 56.8x |
| Market cap (Screener) | ₹151,885 Cr |
| Market-cap bucketi | LARGE_CAP |
| Book value | ₹798.0 |
| Dividend yield | 0.5% |
| Sales (latest)i | — |
| PAT (latest)i | — |
| Net debt (3Y)i | ₹-3,169 Cr |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Capital Goods & Industrials
- Sector strength: 67.88
- Peer avg RS: 29.9% · Avg tech: 67.88 · Avg fund: 57.51
- Sector universe: 12 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹9,554 – ₹10,083 |
| Stop loss | ₹8,743 |
| Target 2M | ₹10,741 |
| Target 4M | ₹11,179 |
| Target 6M | ₹12,856 |
| Reward / Risk (4M) | 0.82× |
| Reward / Risk (6M) | 2.07× |
| Risk per share | ₹1,340 |
| Suggested position size | 4% of portfolio |
Risk score breakdown: ATR 2.2% (+0.5) · Near high -0.4% (+1.0) · RSI 73 (+1.0) · Debt rising (+1.0)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 8864 | 13 | 786 | 51.33 |
| Dec 2025 | 7636 | 13 | 630 | 41.30 |
| Sep 2025 | 6477 | 16 | 693 | 45.54 |
| Jun 2025 | 5906 | 15 | 600 | 39.34 |
Rev QoQ +16.1% · YoY +26.9% · PAT QoQ +24.8% · YoY +7.1% · OPM vs 4Q avg -160 bps
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 28884 | 14 | 2708 | 177.48 |
| Mar 2025 | 22408 | 13 | 2046 | 134.28 |
| Mar 2024 | 18039 | 14 | 1803 | 118.75 |
| Mar 2023 | 14108 | 13 | 1283 | 84.85 |
| Mar 2022 | 12204 | 10 | 917 | 60.80 |
4Y CAGR — Revenue 24.0% · PAT 31.1% · EPS 30.7%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | 236 | -3169 | 20465 |
| Mar 2025 | 202 | -1547 | 13749 |
| Mar 2024 | 161 | -1661 | 12066 |
Debt trend rising · Net cash positive
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | 3811 | -2850 | 961 |
| Mar 2025 | 1809 | -1239 | 570 |
| Mar 2024 | 1296 | -752 | 544 |
OCF/PAT (latest FY) 1.41 → earnings quality: HIGH
N Corporate Events & Insider Activity (90d)
- 2026-06-19 — CORPORATE_ACTION:
📄 Latest Filings Snapshot
- P&L: Sales: 28,884 Cr (YoY +28.9%); NetProfit: 2,708 Cr (YoY +32.4%); EPS: 177.48
- Quarterly: Sales last 3Q: 6,477, 7,636, 8,864 Cr; Net Profit last 3Q: 693, 630, 786 Cr
- Ratios: P/E: 60.4; ROCE: 33.2; ROE: 23.0; Div Yield: 0.47; Book Value: 798; Mkt Cap: 1,51,885
- Investors: Promoters 61.50% | FII 18.21% | DII 7.95% | Public 12.33%
Why selected: VCP-confirmed Stage 2 (vcp=76, inv=65.2) in top-ranked sector Capital Goods & Industrials (strength=68) · 5 positive · 2 negative factors flagged
SATIN · Financial Services
B What the company does
Satin Network Limited (SCNL) is a leading microfinance institution (MFI) with presence in 23 states & union territory and 95,000 villages. The company offers a bouquet of financial products in the Non‐MFI segment (comprising loans to MSMEs), a housing finance subsidiary, and business correspondent services and similar services to other financial Institutions through Taraashna Financial Services Limited (TFSL), a business correspondent company and a 100% subsidiary of SCNL. [1]
Source: Company website · screener.in · live
📈 6-Month Price Action — TradingView-style: Candles · EMAs · Volume · RSI · S/R · Pivots · Volume Profile · Entry/Stop/Targets
Resistance: ₹246 · ₹178 · ₹166
Pivots — PP ₹235 · R1 ₹242 · R2 ₹248 · S1 ₹229 · S2 ₹222
💡 Thesis
Within 5% of 52w high · PAT YoY +636% · Revenue YoY +50% · PAT 4Y CAGR 99%
📈 Technical View
RSI 59.5, 1Y return —%, dist from 52w high -4.7%.
🏦 Fundamental View
Latest qtr revenue 49.6% YoY, PAT 636.4% YoY; 4Y CAGR revenue 22.9% / PAT 99.4%; ROCE —%; debt trend —; OCF/PAT -2.93.
🧭 Sector View
Sector strength 58.14
💰 Valuation
Quantitative valuation not in dossier — defer to qualitative read.
🚀 Key Catalysts
- Watch next quarterly print
⚠️ Key Risks
- OCF/PAT -2.93 weak earnings quality
🎯 Action
Enter ₹228-₹235; stop ₹203; signal BUY.
🏛️ Analyst / Street Consensus (synthesised — no live broker feed)
📐 EPS ₹30.1 × 35x (premium-quality compounder) = ₹1,052 median
- Within 5% of 52w high
- PAT YoY +636%
- Revenue YoY +50%
- OCF/PAT -2.93 weak earnings quality
⚠️ Synthesised from dossier — no live broker poll wired.
Narrative: Synthesised consensus view (no live broker feed): the name screens as a turnaround / cyclical; buy-side would likely weight mean-reversion; watch for re-rating triggers around the next quarterly print. Confirm against live broker reports before sizing.
T Technicals
| Closei | ₹235.43 (2026-06-19) |
| EMA 20/50/200i | ₹227.75 / ₹208.77 / ₹— |
| EMA50 slope (20d)i | 14.48% |
| RSI(14)i | 59.46 |
| ATR(14)i | ₹11.47 (4.87%) |
| 52W High / Lowi | ₹247.00 / ₹135.81 |
| From 52W highi | -4.7% |
| Returns 1M/3M/6M/1Yi | 5.8% / 62.8% / 65.0% / — |
| Vol vs 20d avgi | 0.46x |
F Fundamental Scores
| Piotroski F-scorei | 2 / 6 (approx) |
| Altman Z-scorei | 1.00 (Z′ approx) |
| Beneish M-scorei | -1.89 (watch, simplified) |
| Forensic riski | moderate (derived) |
| ROE / ROCEi | 11.6% (computed) / 60.9% (computed) |
| Revenue growth (3Y)i | 22.9% (4Y CAGR) |
| PAT growth (3Y)i | 99.4% (4Y CAGR) |
| Debt / Equityi | — |
| Promoter holdingi | 36.2% |
| FII / DII holdingi | 3.5% / 5.3% |
| NPMi | 10.6% (computed) |
| EPSi | 30.07 |
Q Quality Score Breakdown
Component sub-scores feeding the composite. Earnings Quality, Sales Growth, Financial Strength and Institutional Backing are each on a 0–10 scale; Composite is the blended 0–100 enhanced fundamental score.
CANSLIM Breakdown (C·A·N·S·L·I·M)
real = computed from financials · proxy = price/volume substitute when financials unavailable · I (institutional) & M (market) are informational and not part of the 25-pt composite.
$ Valuation
| Pricei | ₹235.4 |
| EPS (TTM proxy)i | 30.07 |
| P/E (Screener ratios) | 7.8x |
| Market cap (Screener) | ₹2,601 Cr |
| Market-cap bucketi | MICRO_CAP |
| Book value | ₹259.0 |
| Dividend yield | 0.0% |
| Sales (latest)i | — |
| PAT (latest)i | ₹332 Cr (78.5% YoY) |
| Net debt (3Y)i | — |
Valuation fields come from scores.fundamentals.ratios_summary when available.
Derived P/E is shown only when it materially differs from the parsed Screener ratio.
S Sector Context
- Sector: Financial Services
- Sector strength: 58.14
- Peer avg RS: 25.5% · Avg tech: 58.14 · Avg fund: 52.77
- Sector universe: 16 stocks
🎯 Targets & Risk / Reward
| Entry zone (low–high) | ₹228 – ₹235 |
| Stop loss | ₹203 |
| Target 2M | ₹270 |
| Target 4M | ₹293 |
| Target 6M | ₹337 |
| Reward / Risk (4M) | 1.74× |
| Reward / Risk (6M) | 3.08× |
| Risk per share | ₹33 |
| Suggested position size | 8% of portfolio |
Risk score breakdown: ATR 4.9% (+1.5) · OCF/PAT weak (+1.5)
🛡 Risk Score
0–3 LOW · 4–6 MEDIUM · 7–10 HIGH. Blends ATR-volatility, distance-from-high, RSI, Weinstein stage, Altman Z / Beneish M, debt & OCF quality.
Q Latest Quarterly Results
| Quarter | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 920 | — | 162 | 14.67 |
| Dec 2025 | 740 | — | 72 | 6.51 |
| Sep 2025 | 788 | — | 53 | 4.81 |
| Jun 2025 | 709 | — | 45 | 4.08 |
Rev QoQ +24.3% · YoY +49.6% · PAT QoQ +125.0% · YoY +636.4%
A 5-Year Annual Trajectory
| FY | Revenue (₹ Cr) | OPM % | PAT (₹ Cr) | EPS |
|---|---|---|---|---|
| Mar 2026 | 3143 | — | 332 | 30.07 |
| Mar 2025 | 2595 | — | 186 | 16.85 |
| Mar 2024 | 2234 | — | 436 | 39.46 |
| Mar 2023 | 1549 | — | 5 | 0.56 |
| Mar 2022 | 1378 | — | 21 | 2.76 |
4Y CAGR — Revenue 22.9% · PAT 99.4% · EPS 81.7%
B Balance Sheet (3Y)
| FY | Borrowings (₹ Cr) | Net Debt (₹ Cr) | Total Assets (₹ Cr) |
|---|---|---|---|
| Mar 2026 | — | — | 14387 |
| Mar 2025 | — | — | 11587 |
| Mar 2024 | — | — | 10485 |
C Cash Flow (3Y) & Quality
| FY | Operating CF | Investing CF | FCF proxy |
|---|---|---|---|
| Mar 2026 | -974 | -123 | -1097 |
| Mar 2025 | -563 | -45 | -608 |
| Mar 2024 | -2069 | -24 | -2093 |
OCF/PAT (latest FY) -2.93 → earnings quality: WEAK
N Corporate Events & Insider Activity (90d)
- 2026-06-23 — BOARD_MEETING: Fund Raising
- 🗓 2026-06-23 — UPCOMING BOARD_MEETING: Fund Raising
📄 Latest Filings Snapshot
- P&L: Sales: 3,143 Cr (YoY +21.1%); NetProfit: 332 Cr (YoY +78.5%); EPS: 30.07
- Quarterly: Sales last 3Q: 788, 740, 920 Cr; Net Profit last 3Q: 53, 72, 162 Cr
- Ratios: P/E: 7.83; ROCE: 13.8; ROE: 12.3; Div Yield: 0.00; Book Value: 259; Mkt Cap: 2,601
- Investors: Promoters 36.17% | FII 3.52% | DII 5.30% | Public 54.58%
Why selected: VCP-confirmed Stage 2 (vcp=74, inv=62.7) in top-ranked sector Financial Services (strength=58) · 4 positive · 1 negative factors flagged
⚖️ Full Disclaimer & Use Restrictions
Disclaimer: Not investment advice or a trading recommendation. Educational AI/rules-based market intelligence only. Use, replication, or trading action is at the user's own risk and legal obligation.
This report is provided strictly for educational, research, and learning purposes as part of a journey to understand how AI agents and rules-based agents can be applied to financial-market data. It is not investment advice, trading advice, portfolio advice, a research recommendation, or a solicitation to buy, sell, hold, short, or otherwise transact in any security, derivative, index, fund, or financial instrument. The information, scores, signals, narratives, charts, model outputs, and examples in this report must not be replicated, redistributed, automated, or used with any intent of trading, recommending trades, advising others, managing money, or making financial decisions. Anyone choosing to use, interpret, adapt, copy, replicate, distribute, or act on this information does so entirely at their own risk, responsibility, and legal and regulatory obligation. Agent Adda is not a SEBI-registered investment adviser, research analyst, portfolio manager, broker, or any other SEBI-registered market intermediary. Agent Adda, its creators, contributors, systems, agents, and associated persons accept no responsibility or liability for losses, damages, legal consequences, regulatory consequences, tax consequences, opportunity costs, or any other implications arising directly or indirectly from the use of this information by any person or organization. All market data can be delayed, incomplete, inaccurate, stale, or affected by corporate actions, liquidity, data-provider issues, model limitations, prompt limitations, or rule-design limitations. Users must consult qualified SEBI-registered professionals and independently verify all facts before making any financial or legal decision.